The consistent reduction in cardiovascular risk across various LDL-lowering interventions makes it difficult to argue that pleiotropic effects are the primary drivers of benefit.

“So your argument you so so because there's an argument to be made which is not necessarily the argument we're having today but I I'll and I can't I won't even attempt to steal man it but but I'll just I'll just state it. The argument is that um if you look at all the literature of statins and you see reduction in mortality that doesn't mean that it's because it's lowering LDL. It could be because it's doing something else. It's lowering inflammation or it's doing something else. And you're arguing that that's that's a tough argument to make in light of the all of the MR coupled with all the clinical trial data.”